摘要
目的探讨涎腺粘液表皮样癌多药耐药基因MDR1/P-gp的表达情况及其临床意义。方法应用免疫组织化学技术(EnVision法)检测36例涎腺粘液表皮样癌(其中高分化组21例、低分化组各15例)以及15例正常涎腺组织中MDR1/P-gp的表达。结果MDR1/P-gp在粘液表皮样癌及正常涎腺组织中均有不同程度表达,阳性部位主要见于细胞膜。高分化粘液表皮样癌、低分化粘液表皮样癌和正常涎腺组织MDR1/P-gp表达阳性率分别为81.0%(17/21)、73.3%(11/15)和26.7%(4/15),组间两两比较均具有显著性差异(P<0.01)。结论MDR1/P-gp是涎腺粘液表皮样癌多药耐药产生的重要细胞机制,检测MDR1/P-gp可为临床拟定化疗方案提供依据,也可作为判断涎腺粘液表皮样癌组织分化程度及预后的参考指标。
Objective To investigate the clinical significance of multidrug resitance / P- glycoprotein （MDR1/P-gp） expression in mucoepidermoid carcinoma of the salivary glands. Methods The expression of MDR1/P-gp in 36 cases of epidermoid carcinoma （21 well differentiated, 15 poorly differentiated） and 15 cases of normal salivary gland was detected immuohistochemically by EnVision method. Results MDR1/P-gp expression was found in both mucoepidermoid carcinoma and normal salivary gland with mainly positive staining of membranes. The positive rate of MDR1/P-gp in the well differentiated epidermoid carcinoma, poorly differentiated epidrmoid carcinoma and normal salivary gland was 81.0 % （ 17/21 ）, 73.3 % （ 11 / 15） and 26.7 % （4/ 15） respectively （P 〈 0.01）. Conclusion MDR1/P-gp acts as an important cellular mechanism of multidrug resistance in salivary gland epidermoid carcinoma. MDR1/P - gp detection may be helpful to chemotherapy, and should also be considered as a significance indicator of prognosis and differential degree in epidermoid carcinoma of the salivary glands.
出处
《实用肿瘤学杂志》
CAS
2006年第1期12-13,75,共3页
Practical Oncology Journal
关键词
涎腺肿瘤
粘液表皮样癌
多药耐药基因MDR1/P—gp
免疫组织化学
Salivary gland neoplasm
Mucoepidermoid carcinoma
Multidrug resistance （MDR1）/P- glycoprotein（P- gp）
Immunohistochemistry
